Scribe Therapeutics (SCTX) vs TRex Bio (TRXB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 12, 2026.
Summary
Scribe Therapeutics is the larger company by market cap ($391.3 million vs $385.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | SCTX | TRXB |
|---|---|---|
| Share price | $20.67 | $14.03 |
| Market cap | $391.32M | $385.06M |
| 1-day change | -2.36% | +0.21% |
| EPS (TTM) | $-3.84 | $-2.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.60 | $15.50 |
| 52-week low | $13.50 | $13.50 |
| Distance from 52-week high | -47.80% | -9.48% |
| Analyst consensus | none | — |
| Avg. price target upside | +175.76% | — |
| Average volume | 358.12K | 1.26M |
| Shares outstanding | 18.93M | 27.45M |
| Employees | 82 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
About TRex Bio
TRXB stock →TRex Bio, Inc. operates as a clinical-stage biopharmaceutical company that engages in discovery and development of immunoregulatory medicines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
SCTX vs TRXB FAQ
Which is bigger, Scribe Therapeutics or TRex Bio?
Scribe Therapeutics (SCTX) is larger, with a market capitalization of $391.32M compared with $385.06M for TRex Bio (TRXB).
Are Scribe Therapeutics and TRex Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.